Carcinoma of unknown primary origin with isolated adrenal metastasis: a report of two cases.

The adrenal glands are one of the most common sites of malignant tumor metastasis. However, metastatic adrenal carcinoma of unknown primary origin with localized adrenal gland involvement is an extremely rare condition. Herein, we reported two cases of carcinoma of unknown primary origin with isolated adrenal metastasis. In the first case, back pain was the trigger; while in the second case, the triggers were low fever and weight loss. Metabolic abnormalities such as hypertension and obesity were not detected in either case. Neither patient had relevant previous medical histories, including malignancy. However, both had a long-term history of smoking. Systemic imaging studies revealed only adrenal tumors and surrounding lesions. Primary adrenocortical carcinoma was initially suspected, and chemotherapy including mitotane was considered. However, due to difficulty in complete resection of the tumor, core needle tumor biopsies were performed. Histopathological examination of biopsy specimens led to the diagnosis of carcinoma of unknown primary origin with isolated adrenal metastasis. In both cases, additional laboratory testing showed high levels of serum squamous cell carcinoma-related antigen and serum cytokeratin fragment. Malignant lesions confined to the adrenal glands are rare. As in our cases, it could be occasionally difficult to differentiate non-functioning primary adrenocortical carcinoma from metastatic adrenal carcinoma of unknown primary origin localized to the adrenal gland. If the lesion is unresectable and there are elevated levels of several tumor markers with no apparent hormonal excess, core needle tumor biopsy should be considered to differentiate the primary tumor from the metastatic tumor.

[1]  B. Stuck,et al.  Clinical relevance of CYFRA 21-1 as a tumour marker in patients with oropharyngeal squamous cell carcinoma , 2020, European Archives of Oto-Rhino-Laryngology.

[2]  W. Young,et al.  Comparison between functional and non-functional adrenocortical carcinoma. , 2019, Surgery.

[3]  Eric Baudin,et al.  European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. , 2018, European journal of endocrinology.

[4]  C. Blanpain,et al.  Deciphering the cells of origin of squamous cell carcinomas , 2018, Nature Reviews Cancer.

[5]  S. Kurosaka,et al.  Laparoscopic adrenalectomy for metastatic adrenal tumor , 2014, Asian journal of endoscopic surgery.

[6]  C. Wood,et al.  Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. , 2013, European journal of endocrinology.

[7]  C. Lohse,et al.  Adrenalectomy Improves Outcomes of Selected Patients with Metastatic Carcinoma , 2012, World Journal of Surgery.

[8]  J. Thigpen Combination Chemotherapy in Advanced Adrenocortical Carcinoma , 2012 .

[9]  F. Beuschlein,et al.  High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. , 2010, The Journal of clinical endocrinology and metabolism.

[10]  G. Hammer,et al.  Management of adrenocortical carcinoma. , 2009, The Journal of the National Comprehensive Cancer Network.

[11]  J. Monchik,et al.  Limited value of adrenal biopsy in the evaluation of adrenal neoplasm: a decade of experience. , 2009, Archives of surgery.

[12]  Martin Fassnacht,et al.  Clinical management of adrenocortical carcinoma. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[13]  D. Schteingart Adrenocortical Carcinoma in the United States: Treatment Utilization and Prognostic Factors , 2009 .

[14]  Martin Fassnacht,et al.  Adrenocortical Carcinoma: Clinical Update , 2006 .

[15]  Linda Ng,et al.  Adrenocortical carcinoma: diagnosis, evaluation and treatment. , 2003, The Journal of urology.

[16]  K. Lam,et al.  Metastatic tumours of the adrenal glands: a 30‐year experience in a teaching hospital , 2002, Clinical endocrinology.

[17]  D. Rades,et al.  Localised disease in cancer of unknown primary (CUP): the value of positron emission tomography (PET) for individual therapeutic management. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Y. Chapuis,et al.  Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group , 2001, World Journal of Surgery.

[19]  J. Abbruzzese,et al.  Unknown primary cancer presenting as an adrenal mass: frequency and implications for diagnostic evaluation of adrenal incidentalomas. , 1998, Surgery.

[20]  P. Puech,et al.  Adrenalectomy for a solitary adrenal metastasis from lung cancer. , 1998, The Annals of thoracic surgery.

[21]  R. Bellantone,et al.  The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. , 1996, Surgery.

[22]  H. Sasano,et al.  Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy. , 1995, Human pathology.

[23]  J. Daurès,et al.  Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. , 1993, Cancer research.

[24]  P Blondeau,et al.  Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. , 1990, The New England journal of medicine.